Aldagen, Inc.

Aldagen is focused on the development of identification tools for adult stem cells.

Aldagen was founded as STEMCO Biomedical, Inc. by Michael Colvin, Nelson Chao and Clay Smith, MD. In 2005 the companie’s name was changed to Aldagen, Inc. Aldagen develops and markets products for the identification of adult stem cell populations.

W. Thomas Amick, Chairman & CEO
Ed Field, President & COO
N. Rebecca Haley, MD, VP Clinical & Regulatory Affairs
Andrew Balber, PhD, VP Preclinical Development

Nelson Chao, MD
Michael Colvin, MD
Clay Smith, MD
Robert S. Negrin, MD
Warren Strittmatter, MD
Edmund K. Waller, MD, PhD, FACP

2810 Meridian Parkway Suite 148
Durham, NC 27713
USA
Phone:+1-919-484-2571
Fax:+1-919-484-8792

The background of STEMCO’s technology lies in the measurement of aldehyde dehydrogenase (ALDH), an intracellular enzyme that is highly expressed in haematopoietic stem and progenitor cells.

By means of ALDEFLUOR™, researchers are able to identify stem and progenitor cells due to their high expression of ALDH when using flow cytometry. ALDEFLUOR™ products are distributed worldwide though StemCell Technologies.
ALDECOUNT™ is a labelling tool for adult stem cells using ALDEFLUOR™ technology.
ALDESORT™ was developed for the purification and sorting of stem cells using a fluorescence activated cell sorter (FACS).

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.

The following patents are issued or exclusively licensed to StemCo Biomedical, Inc.: